Collegium Stock Is Getting Beaten As Q2 Earnings Miss Street Estimates; Revises FY21 Guidance

  • Collegium Pharmaceutical Inc COLL reported Q2 adjusted EPS of $0.27, below the consensus of $0.36.
  • The reported EPS of $1.79 was up from $0.23 a year ago and included a one-time non-cash adjustment of $1.52 per share.
  • Sales increased 6.3% Y/Y to $82.9 million, missing the estimate of $84.8 million.
  • Xtampza ER net product revenues were $33.0 million, almost the same as Q2 FY20. Nucynta franchise net product revenues increased from $44.5 million to $49.9 million.
  • Xtampza ER prescriptions grew 6.9% sequentially and 21.7% Y/Y, and Nucynta Franchise prescriptions grew 0.5% Q/Q.
  • Guidance FY21: Collegium decreased Xtampza ER sales to $140.0 - $150.0 million from ealier guidance of $155.0 million - $165.0 million.
  • It raised Nucynta sales from $195 million - $205.0 million, from $185 million - $195 million.
  • It reaffirmed FY21 adjusted EBITDA of $170 million - $180.0 million.
  • Price Action: COLL shares are down 16.8% at $20.69 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!